Oral vs. Injectable GLP-1 Agonists: Which is Best for Cardiometabolic Health?

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications highly effective for weight management and improving cardiometabolic health in individuals with overweight or obesity. Both oral and subcutaneous (injectable) formulations are available, offering different administration routes and potential efficacy profiles. However, a comprehensive, direct comparison of the cardiometabolic effects of oral versus subcutaneous GLP-1 mono-agonists across a broad range of outcomes has been lacking.

Both oral and subcutaneous GLP-1 receptor mono-agonists significantly improved cardiometabolic profiles compared to placebo across the analyzed studies. Subcutaneous semaglutide demonstrated the most pronounced effects on weight loss, achieving a mean difference of -12.8 kg (95% CI: -14.8 to -10.8) compared to placebo. Oral semaglutide also showed significant weight reduction, with a mean difference of -5.6 kg (95% CI: -7.2 to -4.0) versus placebo. Subcutaneous semaglutide consistently outperformed other GLP-1 mono-agonists, including oral semaglutide and subcutaneous liraglutide, across multiple key cardiometabolic parameters, particularly for weight reduction and glycemic control. For systolic blood pressure, subcutaneous semaglutide reduced it by -5.2 mmHg (95% CI: -6.5 to -3.9), while oral semaglutide showed a reduction of -3.1 mmHg (95% CI: -4.3 to -1.9). Furthermore, subcutaneous semaglutide reduced HbA1c by -0.8% (95% CI: -1.0 to -0.6) and significantly improved lipid profiles, including a 15% reduction in triglycerides.